• Research Faculty

  • A photo of Michael Absalon.

    Michael J. Absalon, MD, PhD

    focuses on developing new therapies and combinations of therapies for pediatric leukemias and lymphomas. He is currently investigating the therapeutic potential of combining the new targeted drug sorafenib with conventional chemotherapy for relapsed AML.


    A photo of Denise Adams.

    Denise M. Adams, MD Marjory J. Johnson Chair of Vascular Tumor Translational Research

    is a nationally recognized expert on vascular anomalies with a keen interest in rare vascular tumors and life threatening malformations. She leads a clinical and translational research program to develop new therapies for these conditions and currently is the PI of a clinical study of sirolimus, a mTOR inhibitor, in the treatment of complicated vascular anomalies, the first trial of a new therapy for these conditions.


    A photo of Karen Burns.

    Karen C. Burns, MD, MS Director, Cancer Survivorship Center

    conducts research on cancer survivorship and serious late effects of cancer treatment, including obesity, heart problems, fertility issues, increased risk of second cancers, and long-term outcomes of cancer survivors. She is also leading development of a fertility preservation program for children and adolescents undergoing chemotherapy as well as other unique medical and support services for adolescent and young adult cancer patients.


    A photo of Lionel Chow.

    Lionel M. L. Chow, MD, PhD Member, Cancer Biology and Neural Tumors Program

    studies high-grade gliomas, which are aggressive brain tumors in adults and children with limited treatment options. Using a combination of novel and robust laboratory models coupled with the study of human tumor material, the lab’s goals are to better understand the cellular origins and molecular underpinnings of these diseases in order to design and test novel therapies that will hopefully improve patient outcome.
    Visit the Chow Lab


    A photo of Dr. Biplab Dasgupta.

    Biplab Dasgupta, PhD, MS Member, Cancer Biology and Neural Tumors Program

    focuses on the integration of metabolic and signaling pathways in neural cells including neural and brain cancer stem cells. He is particularly interested in understanding the link between cellular energy sensing pathways with cellular signaling circuits that are controlled by growth factors and their receptors. Mouse models are used to understand the development of high grade human and mouse brain tumor (glioma).
    Visit the Dasgupta Lab.


    A photo of Mariko DeWire.

    Mariko D. DeWire, MD

    focuses on developing novel therapeutics to treat children with all central nervous system tumors including young children (less than 4 years of age), very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Additionally, she has an interest in maximizing the quality of life in children and young adults diagnosed with brain tumors.


    A photo of Rachid Drissi.

    Rachid Drissi, PhD

    studies replicative senescence or cellular aging, believed to be a tumor suppressor mechanism by which normal cells limit cell proliferation to prevent genome instability and cancer. The long-term goal of our research program is to examine telomere disruption signaling to DNA damage pathway and senescence. We are also developing a combination therapy that includes telomere disruption to improve the outcome for children with brain tumors. 


    A photo of Maryam Fouladi.

    Maryam Fouladi, MD, MSc, FRCPC Medical Director, Neuro-Oncology Program

    serves as chair for the CNS Tumor New Agents/Relapse Committee for the Children’s Oncology Group, and as member of the steering committee for the COG CNS Tumor Committee and the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair for active open clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.


    A photo of James Geller.

    James I. Geller, MD Medical Director, Kidney and Liver Tumors Program

    focuses on children and young adults affected by solid tumors. Dr. Geller's expertise is recognized internationally, as witnessed by his appointments to the Children's Oncology Group (COG) Renal Tumor, Liver Tumor, Retinoblastoma and Central Nervous System (Brain Tumor) Committees. Dr. Geller directs and spearheads local and national studies in these areas, with an emphasis on novel therapeutics.